Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Apogee Therapeutics, Inc. Common Stock

Healthcare US APGE

132.63USD
42.25(46.75%)

Last update at 2026-06-22T15:11:00Z

Day Range

132.50133.00
LowHigh

52 Week Range

34.3495.31
LowHigh

Fundamentals

  • Previous Close 90.38
  • Market Cap6782.42M
  • Volume37809696
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-284.17699M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-4.22

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -255.56500M -182.12800M -83.98500M -39.78500M
Minority interest - - - -
Net income -255.84300M -182.14600M -83.98500M -39.78500M
Selling general administrative 70.88M 49.01M 24.58M 2.94M
Selling and marketing expenses - - - -
Gross profit -1.41800M -0.18900M - -
Reconciled depreciation 1.42M 0.19M - -
Ebit -285.59500M -216.87000M -93.09600M -30.76052M
Ebitda -284.17700M -216.68100M -93.00300M -30.72700M
Depreciation and amortization 1.42M 0.19M 0.09M 0.03M
Non operating income net other - - - -
Operating income -285.59500M -216.87000M -93.00300M -30.72700M
Other operating expenses 285.60M 216.87M 93.00M 30.73M
Interest expense - - 0.00000M 9.15M
Tax provision 0.28M 0.02M - -
Interest income 30.03M 34.74M 9.02M 0.09M
Net interest income 30.03M 34.74M 9.02M -9.05800M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.28M 0.02M -0.09300M -0.03352M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 284.18M 216.87M 93.00M 30.73M
Cost of revenue 1.42M 0.19M - -
Total other income expense net 30.03M 34.74M 9.02M -9.05800M
Discontinued operations - - - -
Net income from continuing ops -255.84300M -182.14600M -83.98500M -39.78500M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 937.13M 753.95M 401.40M 152.06M
Intangible assets - - - -
Earning assets - - - -
Other current assets 11.17M 4.36M 2.95M 0.06M
Total liab 33.25M 37.16M 21.49M 9.98M
Total stockholder equity 903.88M 716.79M 379.91M -39.78500M
Deferred long term liab - - - -
Other current liab 23.18M 24.25M 17.31M 9.56M
Common stock 0.00100M 0.00100M - 4.39M
Capital stock 0.00100M 0.00100M 0.00000M 0.00000M
Retained earnings -561.75900M -305.91600M -123.77000M -39.78500M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 131.55M 141.79M 118.32M 151.89M
Cash and equivalents - - - -
Total current liabilities 27.91M 28.56M 20.56M 9.98M
Current deferred revenue - - - -
Net debt -122.70000M -129.95800M -116.28200M -151.89000M
Short term debt 3.50M 3.23M 1.10M -
Short long term debt - - - -
Short long term debt total 8.85M 11.83M 2.03M -
Other stockholder equity 1464.56M 1021.79M 503.35M 39.78M
Property plant equipment - - - -
Total current assets 741.36M 529.71M 398.41M 152.06M
Long term investments 172.73M 210.42M - -
Net tangible assets - - - -
Short term investments 598.64M 378.86M 277.14M 0.00000M
Net receivables - 4.70M - -
Long term debt - - - -
Inventory - - - -
Accounts payable 1.22M 1.07M 2.14M 0.42M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 1.08M 0.92M 0.33M -221.64500M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 181.40M 0.50M 0.10M -
Deferred long term asset charges - - - -
Non current assets total 195.78M 224.24M 3.00M 0.00000M
Capital lease obligations 8.85M 11.83M 2.03M 0.00000M
Long term debt total - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -174.42700M -300.46200M -273.91000M 0.00000M
Change to liabilities - - - -
Total cashflows from investing activities -179.57400M -300.46200M - -
Net borrowings - - - -
Total cash from financing activities 396.49M 495.11M 315.39M 0.18M
Change to operating activities - - - -
Net income -255.84300M -182.14600M -83.98500M -39.78500M
Change in cash -10.53400M 23.47M -33.57400M -16.24338M
Begin period cash flow 142.08M 118.61M 151.89M 168.13M
End period cash flow 131.55M 142.08M 118.32M 151.89M
Total cash from operating activities -227.45000M -171.17400M -74.76100M -16.42700M
Issuance of capital stock 389.63M 493.48M 315.39M 168.32M
Depreciation 1.42M 0.19M - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities 396.49M 1.63M 0.32M 0.18M
Change to netincome - - - -
Capital expenditures 5.15M 1.15M 0.17M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -15.47800M -2.00200M 6.11M 9.81M
Stock based compensation 46.28M 23.33M 6.10M 2.14M
Other non cash items -3.82400M -10.54700M -2.98400M 11.40M
Free cash flow -232.59700M -172.32600M -74.92800M -16.42700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
APGE
Apogee Therapeutics, Inc. Common Stock		 42.25 46.75% 132.63 - - - 7.61
NVO
Novo Nordisk A/S		 2.50 5.78% 45.69 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.55 1.23% 457.18 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.77 1.60% 600.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics, Inc. Common Stock

Building 17, Waltham, MA, United States, 02453

Key Executives

Name Title Year Born
Dr. Michael Thomas Henderson M.D. CEO & Director 1990
Ms. Jane Pritchett V. Henderson Chief Financial Officer 1966
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer 1986
Dr. Rebecca Dabora Ph.D. Chief Technical Officer 1959
Ms. Noel Kurdi Vice President of Investor Relations NA
Mr. Matthew Batters J.D. General Counsel 1976
Ms. Emily Cox VP & Head of People NA
Ms. Wendy Aspden-Curran Senior Vice President of Clinical Operations NA
Dr. Drew Badger Ph.D. Senior VP and Head of Regulatory Affairs & Toxicology NA
Ms. Monica Forbes Senior Vice President of Finance 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.